Agoracom Blog Home

Posts Tagged ‘Cannabis’

North Bud Farms $NBUD.ca Announces Annual General and Special Meeting on December 16th and the Closing of the First Tranche of its Non-Brokered Private Placement of Secured Convertible Debenture Units $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 4:50 PM on Wednesday, November 6th, 2019
  • Annual General and Special Meeting at 1:00 p.m. on Monday, December 16, 2019 at the office of McMillan LLP World Exchange Plaza, Suite 2000, Ottawa, Ontario.  
  • Announce that on November 6, 2019, the board authorized the issuance of up to 4,000 convertible debenture units of the Company at a price of $1,000 per Unit for total gross proceeds of up to $4,000,000.

TORONTO, Nov. 06, 2019 — North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company”) today announces that the Company will hold its Annual General and Special Meeting at 1:00 p.m. on Monday, December 16, 2019 at the office of McMillan LLP World Exchange Plaza, Suite 2000, Ottawa, Ontario.  

Additionally, the Company is pleased to announce that on November 6, 2019, the board authorized the issuance of up to 4,000 convertible debenture units (“Units”) of the Company at a price of $1,000 per Unit for total gross proceeds of up to $4,000,000. Based on this decision the Company will not be closing any additional tranches of the previously announced equity private placement.

Each Unit is comprised of one $1,000 principal amount of secured convertible debenture (a “Convertible Debenture”) accruing interest at 10.0% per annum, payable semi-annually in arrears until maturity, and 2,000 common share purchase warrants of the Company (each, a “Warrant”). The Convertible Debentures will have a maturity date of 36 months from the date of issuance.

Each Convertible Debenture shall be convertible into common shares in the capital of the Company (each, a “Conversion Share”) at a price of $0.30 per Conversion Share.

Each Warrant entitles the holder thereof to acquire one common share in the capital of the Company (each, a “Warrant Share”) for an exercise price of $0.25 per Warrant Share for a period of 18 months following the closing date.

The Convertible Debentures are direct secured obligations of the Company and rank pari passu in right of payment of principal and interest with all other Convertible Debentures issued under the Offering.

The Company is pleased to announce that on November 6, 2019 it closed an initial tranche of 1,264 Units for gross proceeds of $1,264,000. These Units were purchased by one insider and existing shareholders. The Company intends to close the remaining Units in one or more tranches over the coming weeks.

Ryan Brown, the Chief Executive Officer, of the Company participated in the private placement and beneficially acquired 664 Units for a total proceeds of $664,000. The purchase constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The issuance is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as the fair market value of the Units issued to or the consideration paid by such insider did not exceed 25% of the Company’s market capitalization.

Certain finders (the “Finders”) received a cash commission on the sale of the Offering of $48,000. The Finders also received 48,000 compensation warrants (the “Compensation Warrants”), each carrying the right to purchase 3.3333 common shares in the capital of the Company at a price of $1.00 per Compensation Warrant for a period of 18 months from the closing date.

The proceeds of the Offering will be used by the Company for expansion of the Company’s facilities and for general corporate and working capital purposes.

The Convertible Debentures, Warrants and Compensation Warrants issued pursuant to the Offering and any common shares in the capital of the Company issued on conversion of the Convertible Debentures or exercise of the Warrants or Compensation Warrants are subject to a statutory hold period in Canada of four months and one day following the closing date in accordance with applicable securities laws, which shall expire on March 7, 2020. Additional resale restrictions may be applicable under the laws of other jurisdictions, if any.

The securities of the Company have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities of the
Company in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Corporate Update
Since the submission of our evidence package to Health Canada, the Company has received some minor comments from the regulators all of which have been responded to within 24 hours. The Company will update shareholders with any material developments related to the application process.

About North Bud Farms Inc.
North Bud Farms Inc., through its wholly owned subsidiary GrowPros MMP Inc., is pursuing a licence under The Cannabis Act.  The Company has built a state-of-the-art purpose-built cannabis production facility located on 135 acres of Agricultural Land in Low, Quebec, Canada. NORTHBUD through its wholly owned U.S. subsidiary, Bonfire Brands USA has entered into agreements to acquire assets in California and Nevada.

For more information visit: www.northbud.com

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements that include, but are not limited to, statements related to the intended use of proceeds from the Offering. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms Inc.’s final long form prospectus dated August 21, 2018, which is available under the issuer’s SEDAR profile at www.sedar.com

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected] 

NORTHBUD $NBUD.ca – #Cannabis may be helping some #Canadians cope with #PTSD symptoms: study $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 10:30 AM on Wednesday, November 6th, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE
—————————–

Cannabis may be helping some Canadians cope with PTSD symptoms: study

  • Cannabis use could be helping Canadians cope with some of the effects of post-traumatic stress disorder, according to new research from the BC Centre on Substance Use and University of British Columbia. 

By: Jeremiah Rodriguez

Cannabis use could be helping Canadians cope with some of the effects of post-traumatic stress disorder, according to new research from the BC Centre on Substance Use and University of British Columbia. 

Cannabis use could be helping Canadians alleviate some of the effects of post-traumatic stress disorder, according to new research from the BC Centre on Substance Use and University of British Columbia.

The study, published in the Journal of Psychopharmacology, found people with PTSD who were not using cannabis were “far more likely” to have suicidal thoughts and suffer from severe depression than self-proclaimed pot users, according to data taken from Statistics Canada’s 2012 Canadian Community Health Survey – Mental Health.

People who suffered trauma — including survivors of acute injury, violence, conflict and disasters — suffer at disproportionately higher rates of depression, suicide and substance abuse than the general population.

The research team found that among non-cannabis users, PTSD was “significantly associated” with a major recent depressive episode and suicidal thoughts.

More specifically, PTSD sufferers who didn’t use pot were seven times more likely to have a depressive episode and nearly five times more likely to have suicidal thoughts compared to non-cannabis users without PTSD.

“Among the cannabis-non-using population, there was a strong association between having PTSD and experiencing these indicators of severe mental distress,” lead author Stephanie Lake said during a phone interview with CTVNews.ca, adding that pot users didn’t see this same association.

Her research was the first to track the relationship between PTSD, cannabis use and “severe mental health outcomes” among the average Canadian population, according to a university press release.

Lake, a research assistant at the British Columbia Centre on Substance Use, said this was the first study examining how PTSD’s connection to suicidal thoughts or severe depression “could be interrupted by the use of cannabis.”

Her study also found one in four Canadians with PTSD said they used cannabis — which is “remarkably high” compared to the prevalence of pot use among the general Canadian population (which is an estimated 11.4 per cent).

STUDY DIDN’T SHOW CAUSAL LINK BETWEEN POT, PTSD RATES

Lake stressed her study didn’t outright show a definitive, causal link between cannabis use and decreased PTSD symptoms.

The PhD candidate at UBC’s School of Population and Public Health said the study “didn’t tell us whether people are successfully using cannabis to treat PTSD … but it is a promising signal that there might be a therapeutic (benefit) to cannabis use.”

Of the 24,089 respondents to the 2012 Canadian Community Health Survey – Mental Health, 420 people had a clinical diagnosis of PTSD.

From those with PTSD, 106 of them — 28 per cent — said they used cannabis. This rate is nearly three times the rate of pot users without PTSD (11.2 per cent).

Lake’s overall findings could be extremely helpful to many Canadians, as the study mentions that 9.2 per cent of Canadians have PTSD — one of the highest prevalence rates for the disorder in the world.

HOW CANNABIS POTENTIALLY HELPED WITH PTSD

Lake explained that cannabinoid receptors in people’s bodies help regulate mood and sleep, and some research suggests that trauma from PTSD could compromise this endocannabinoid system.

“So when you introduce external cannabinoids (from pot products) to the body, it might help to get the system working as normal again,” she suggested.

Lake also noted that, according to the study, PTSD patients did have cannabis-use disorders at a higher rate than the general population.

In a press release, senior author Dr. M-J Milloy, BCCSU research scientist and Canopy Growth Professor of Cannabis Science at UBC, said that “we’re only just beginning to understand what the therapeutic potential of cannabis may be for a variety of health conditions.”

“These findings are promising, and merit further study in order to fully understand the benefits of cannabis for people living with PTSD,” he added.

Lake added that UCB researchers are currently conducting a clinical trial looking at the effectiveness of cannabis products in specifically treating PTSD.

Source: https://www.theloop.ca/ctvnews/cannabis-may-be-helping-some-canadians-cope-with-ptsd-symptoms-study/

NORTHBUD $NBUD.ca – #Cannabis Canada: #Pot industry added nearly $8B to #GDP in August, #StatsCan says $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 4:31 PM on Tuesday, November 5th, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE
—————————–

Cannabis Canada: Pot industry added nearly $8B to GDP in August, StatsCan says

Cannabis sales in Canada expected to double next year to $3.16B: analyst 

Canaccord Genuity cannabis analyst Matt Bottomley expects revenue in Canada’s legal pot sector to more than double next year despite slower-than-expected growth. Bottomley said in a research note to clients that Canada’s cannabis industry should expect $3.16 billion in revenue in 2020, up from the $1.46 billion forecast for 2019. He added Canada’s cannabis retail figures should see a five per cent reduction in overall sales in September from the prior month to $121 million, but said subsequent growth should advance at a five-per-cent monthly clip. Bottomley expects growth in the recreational market to increase by just 7.5 per cent in 2020. Alongside its latest estimates for the Canadian cannabis industry, Canaccord’s analysts have revised sales projections for some of the country’s largest licensed producers such as Canopy Growth, Aphria and Aurora Cannabis.

BRNT secures multiyear white label deal with Valens GroWorks for 2.2M vape pens

BRNT Group, a company which has made its name making high-end cannabis accessories, is getting into the vape game. The company announced on Thursday a partnership with Valens GroWorks to produce a minimum of 2.2 million vape pens over the next two years. The deal, which is believed to be one of the largest publicly announced multi-year white label agreements, is expected to generate over $50-million in gross revenue for Valens, according to a statement released by both companies. The vape devices are expected to be available in select markets starting in the first quarter of next year and roll out across Canada later in the year.

Canadian pot producer hires helicopter to avoid possible frost on outdoor grow

Looking for a novel way to ensure your outdoor crop won’t be impacted by frost? Give your local helicopter pilot a call. That’s what 48North did, according to an Instagram post published by Devin Piche, the company’s master grower. A helicopter is able to float above an agricultural crop and essentially suck up cold air upward away from plants which could be damaged by a potential frost. “The helicopter was used to move warm air in a temperature inversion down into the crop area to keep the temperature above freezing,” according to Connor Whitworth, a 48North spokesperson. The cannabis producer is harvesting the remaining cannabis plants it is growing in its Good:Farm facility. Whitworth declined to further comment on 48North’s outdoor harvest, which it has previously stated expects to yield 40,000 kilograms of cannabis.

Alberta eyes 500 pot shops by 2021, no consumption lounges planned: regulatory official

Alberta is already the country’s market leader in the pot retail space – and it looks like it could get even larger.  Alberta Gaming, Liquor and Cannabis expects its store count to grow to over 500 within two years, according to the Calgary Herald, citing an official with the provincial regulator. The regulator has already green lit 306 retail outlets across the province, a number that will likely grow by 200 by 2021. However, cannabis consumption lounges don’t appear yet to be coming out anytime soon and would require legislative approval to establish those types of facilities, the official said.

Canada’s cannabis industry contributed nearly $8B to GDP in August: StatsCan

Canada’s cannabis sector – both the legal and illegal market – contributed $7.92 billion to the country’s gross domestic product in August, a figure that continues to grow from the $7.02 billion last October when recreational cannabis was legalized and above the revised $7.79 billion mark made in July, according to new data published by Statistics Canada on Thursday. The StatsCan figures also show Canada’s legal cannabis industry has grown by 116 per cent in the first 11 months since recreational marijuana was legalized. The black market’s cannabis output has fallen by 22 per cent in that same time, according to StatsCan estimates.

Source: https://www.bnnbloomberg.ca/cannabis-canada-pot-industry-added-nearly-8b-to-gdp-in-august-statscan-says-1.1341044

NORTHBUD $NBUD.ca – #Edible #CBD Products Offer Consumers a New Health Trend $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 4:00 PM on Thursday, October 31st, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE
—————————–

Edible CBD Products Offer Consumers a New Health Trend

  • North American consumer spending on cannabis-infused foods and drinks reached USD 1.5 Billion in 2018, according to data compiled by Arcview Market Research and BDS Analytics,
  • By 2022, the two firms suggest that edible sales are on track to reach USD 4.1 Billion

NEW YORK, Oct. 31, 2019 – Consumer trends constantly require industries to adapt in order to thrive among the competition. Specifically, the food and beverage industry is one of the fastest evolving markets because of constant changes in consumer demands. Nowadays, the increasing demand for healthier and more organic options is prompting manufacturers to produce alternatives to sugar-packed drinks and fatty snacks. Instead, consumers are looking for products that are processed with healthier sustainable ingredients, proteins, vitamins, and antioxidants. Notably, many consumers have turned to the beverage industry for functional drinks such as kombucha. A functional drink is a type of beverage that typically conveys a health benefit such as being packed with performance-enhancing agents like nootropics and amino acids. Consequently, the growing demand in the functional beverage market sparked interest within the CBD market. CBD is a derivative of the hemp plant, which falls under the cannabis family.

Typically, cannabis is associated with its marijuana component, which causes psychoactive effects because of its heavy THC concentrate. However, hemp does not cause psychoactive effects because the main compound is CBD. THC and CBD are widely different in their biological makeup, but because they derive from the cannabis plant, regulators deemed both compounds to be unsafe for consumers. However, extensive research has uncovered that CBD provides therapeutic and health benefits, which then led to the rapid emergence of CBD-based products. As such, North American consumer spending on cannabis-infused foods and drinks reached USD 1.5 Billion in 2018, according to data compiled by Arcview Market Research and BDS Analytics, By 2022, the two firms suggest that edible sales are on track to reach USD 4.1 Billion.

Typically, most people consume CBD to simply relax. However, clinical trials have proven that CBD can also provide medical benefits. Specifically, patients suffering from chronic ailments such as severe pain, cancer, arthritis, and epilepsy can consume CBD drinks to subdue the symptoms. And while CBD is quickly permeating throughout global regions, the North American market is the primary driver because of legality stance. Canada moved to legalize cannabis entirely back in late 2018, which prompted a spur of recreational demand. On the other hand, the U.S. passed the Farm Bill in 2018, which legalized hemp-derived CBD products. Shortly after, stores across the nation began to commercialize CBD goods.

Now, consumers can easily purchase products such as tinctures, topicals, oils, and edibles at their local convenience stores or online e-commerce platforms. However, the CBD beverage market is one of the most popular segments because consumers can easily purchase a CBD-based tincture and add droplets of CBD into their beverage. Generally, CBD can be found within beverages such as soda, juice, coffee, wine, water, and even alcohol. However, consumers can also add CBD-based powders into their beverages and some producers have even mentioned that powders are much better in terms of solubility. Overall, the cannabis-infused beverage industry is quickly gaining traction, however, some beverage producers are still evaluating the industry.

Nonetheless, a handful of corporations such as the alcohol industry, have already dove into the marketplace and are already marking their presence.  “Everyone in the industry recognizes that CBD-infused beverages are going to be one of the largest category opportunities in all of CBD,” said Ben Witte, the Founder and Chief Executive Officer of Recess, a company producing CBD-infused sparkling water. “As a result of that, a lot of the suppliers in the supply chain have innovated to create a format that is soluble in beverages.”

Source: https://www.prnewswire.co.uk/news-releases/edible-cbd-products-offer-consumers-a-new-health-trend-884112693.html

NORTHBUD $NBUD.ca – ‘It is quite amazing’: #CBD oil entering the mainstream $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 10:26 AM on Friday, October 18th, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE
—————————–

‘It is quite amazing’: CBD oil entering the mainstream

By James Pugh

Some people are infusing the cannabis extract in cocktails, others are buying it in the form of dog treats, while many more are using it as a form of pain relief.

Unlike tetrahydrocannabinol, the psychoactive extract of the cannabis plant commonly known as THC, cannabidiol doesn’t cause users to get high.

And it is legal in the UK, assuming it does not contain one part in 10,000 of THC.

“When I first got involved with CBD I wanted to know what it was all about,” says Richard Butler, part of the management team at CBD Virtue, between Bridgnorth and Wolverhampton.

“It is still new in the UK.”

Some of the products

His company uses CBD to make products such as tablets, oils, body creams and balms.

Mr Butler says people are turning to CBD products to alleviate symptoms from physical ailments like pain and inflammation as well as mental ones like anxiety and depression.

At present, use of the oil is largely unregulated, and clinical trials into its usefulness are ongoing, but Mr Butler says he has witnessed its benefits.

“You learn more from the responses and feedback you get from customers,” he says. “It helps with pain relief, mental issues, anxieties.

“It also helps with eczema, psoriasis and acne – it is quite amazing actually.

“A lot of our initial customers were 40 plus and many were buying products for the younger generation.

Dean Burke using a CBD Pod Filler at CBD Virtue

“What has amazed me is the amount of depression and anxiety that exists among teenagers up to people in their late 20s.”

CBD oil, its proponents say, offers numerous benefits, from pain relief to reducing anxiety. As an anticonvulsant, it may also help treat neurological disorders such as epilepsy and multiple sclerosis.

CBD is also one of the biggest buzzwords in food and drink. It has been hailed the next big thing, with more and more chefs and producers using the products in their recipes.

After already taking other countries by storm, more businesses in the UK are looking to tap into the market.

Ross Burke viewing the product range at CBD Virtue

Mr Butler insists he has seen some significant success stories of people using the product for remedial purposes.

“I know someone who suffered with Parkinson’s for years who every time they woke up their whole body would be shaking and during the day they would shake out of control,” he says.

“I said ‘try this’ and within two weeks they went from their whole body shaking to feeling a slight twitch in their first finger and thumb.

“I am not allowed to say it cures cancer, but cancer sufferers are using it. There was someone who had skin cancer and it helped clear up blisters on their skin.

“My partner was on a lot of medication for various things and after taking four or five drops a day her stress and anxiety has gone.”

The product’s relationship to recreational cannabis also means that some people are reluctant to accept its use, and the medical benefits it provides have still to be proven beyond doubt.

But Mr Butler insists that the hemp-derived oil should be trusted.

“It is from a natural product that has been around for years,” he says. “Initially people were sceptical because it relates to cannabis. Yes, it is derived from cannabis plant, but the ‘high’ has been removed with the remedial side left behind.

The management team at CBD Virtue: Dean Burke, Richard Butler, Shannon Fyfe and Ross Burke

“We had the over 50s saying ‘ yeah but it’s cannabis, it’s cannabis’, but once you have explained to them they are willing to try it.

“A big part of my role has been educational. I would spend about two hours a day on Facebook educating people and answering a lot of questions.

“Initially it is getting people to try it, then after they see how effective it is they speak about it to their friends and family – a lot of it comes down to word of mouth.”

The plant is grown in Colorado in the USA, and a powdered form of the product is sent to the UK for the oil to be extracted by Richard’s team.

CBD Virtue employs 16 people, and is looking to double that by moving to larger premises to cope with demand.

Richard says: “We have a lab which is about 15ft by 20ft where a lot of our mixing is done. We also have another facility where we do the bottling up and everything else.

Jean Price packing up an order at CBD Virtue

“We are looking for larger premises due to growing demand and want to stay local. We employ 16 people and with the way things are going we are looking to double the workforce.”

Sales of products containing CBD have skyrocketed by 99 per cent in the UK, according to data.

Analysis by deals firm Wowcher suggests purchases of CBD products have almost doubled in 2019, with an increasing number of Brits trying the ingredient.

“The industry is exploding,” Mr Butler says. “Initially as a company we had a slow start with various issues with banks and online payment systems, but we have got more and more people on board who know how to get around these things.

Source: https://www.expressandstar.com/news/business/2019/10/17/it-is-quite-amazing-cbd-oil-entering-the-mainstream/

North Bud Farms $NBUD.ca Announces the Appointment of Sean Homuth as Acting Chief Financial Officer $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 10:03 AM on Thursday, October 17th, 2019
  • Announce the appointment of Sean Homuth as Acting Chief Financial Officer, effective today
  • Mr. Homuth’s permanent role as CFO will commence upon receiving Health Canada security clearance required for all Officers and Directors of the Company

TORONTO, Oct. 17, 2019 — North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company”) is pleased to announce the appointment of Sean Homuth as Acting Chief Financial Officer (CFO), effective today. Mr. Homuth’s permanent role as CFO will commence upon receiving Health Canada security clearance required for all Officers and Directors of the Company. 

“As NORTHBUD expands its presence into the USA with the anticipated closing of its previously announced letters of intent with the Qlora Group (California) and Nevada Botanical Science (Nevada), we are strategically adding additional expertise in international business and finance,” said Ryan Brown, CEO of North Bud Farms Inc.

Mr. Homuth brings extensive experience with both Canadian and U.S. publicly traded organizations both in industry as well as from a client perspective during his tenure at Ernst & Young and, more recently, as an independent consultant. Previously, Mr. Homuth was Chief Financial Officer at Orezone Gold Corporation (and Vice President, Finance and Administration for its predecessor company, Orezone Resources Inc.) a publicly listed company headquartered in Canada with operations in West Africa. At Orezone Mr. Homuth led a global team of finance professionals and was involved in over $800 million in financings and M&A transactions with the company and its predecessor. Mr. Homuth holds accounting designations in both Canada (CPA, CA) and the United States (CPA – Illinois).

“We are pleased to welcome Sean to our dynamic team as NORTHBUD expands its footprint into the USA,” stated Ryan Brown, CEO of North Bud Farms Inc. “Sean brings specialty experience in accounting and finance for international companies as well as a profound knowledge of capital markets, having worked with and advised many public companies over the years. He joins NORTHBUD at an exciting time in its development as his leadership and experience will be essential in executing our strategic plan and taking the company to its next level of growth.”

Brendan Stutt, the Company’s incumbent CFO, who has made invaluable contributions to the Company’s financial leadership and culture, will work to ensure a smooth transition and will remain with the Company in a non-executive role.

Mr. Brown stated: “We would like to thank Brendan for his contributions to the Company, in particular the successful listing of NORTHBUD on the Canadian Securities Exchange.” 

About North Bud Farms Inc.
North Bud Farms Inc., through its wholly owned subsidiary GrowPros MMP Inc., is pursuing a licence under The Cannabis Act. The Company has built a state-of-the-art purpose-built cannabis production facility located on 135 acres of Agricultural Land in Low, Quebec, Canada. NORTHBUD through its wholly owned U.S. subsidiary, Bonfire Brands USA has entered into agreements to acquire assets in California and Nevada.

For more information visit: www.northbud.com

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements and information included in this press release that, to the extent they are not historical fact, constitute forward-looking information or statements (collectively, “forward-looking statements”) within the meaning of applicable securities legislation. Forward-looking statements, including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. This press release contains forward- looking statements including those relating to the entering into of the Definitive Agreement and closing of the Transaction with the Qlora Group and Nevada Botanical Science. Forward-looking statements are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risk factors included in the Company’s final long form prospectus dated August 21, 2018, which is available under the Company’s SEDAR profile at www.sedar.com. Accordingly, readers should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect information, events, results, circumstances or otherwise after the date hereof or to reflect the occurrence of unanticipated events, except as required by law including securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]

The Miracle That Is #CBD, Might Help Breast Cancer Patients Too – SPONSOR: Empower Clinics $CBDT $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 12:08 PM on Friday, October 11th, 2019

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics
  • Patient database of over 165,000 patients 
  • Platform generating $4MM USD in revenue annually (2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Launching CBD extraction facility
  • First extraction system capacity = 6,000 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025

The Miracle That Is CBD, Might Help Breast Cancer Patients Too

By: Erika W. Smith  

CBD is in our lattes, moisturizers, and chocolates, but what about its use in a hospital setting instead of your local café or beauty store? Although more study is needed, research suggests that CBD may have the potential to help relieve certain side effects of chemotherapy.  

CBD is short for cannabidiol, which is one of the many compounds found in cannabis and hemp. Unlike tetrahydrocannabinol (THC), it’s non-psychoactive. Manufacturers have found a way to separate CBD from the plants, and the Agriculture Improvement Act of 2018 (aka the Farm Bill) legalized hemp-derived CBD that contains no more than 0.3% THC and is made from hemp grown by licensed producers. (That’s why you’ve seen so many CBD products recently.) But so far, the Food and Drug Administration has only approved one form of CBD: Epidiolex, a drug containing a purified marijuana-derived form of CBD, which is used for preventing seizures caused by rare forms of epilepsy. 

However, medical marijuana — which contains CBD as well as THC and other compounds — has been used by cancer patients for many years. In 1996, California became the first state to legalize marijuana for medical use. And although marijuana is still illegal on a federal level, it’s currently legal for medical use in 33 states — and it’s approved for use by cancer patients in every state in which medical marijuana is legal. (For comparison, medical marijuana is approved for use by patients with Crohn’s disease in only 27 states.) Additionally, the FDA has approved two chemically pure drugs based on marijuana compounds to treat nausea and vomiting in cancer chemotherapy patients.   

A 2016 review of medical marijuana’s use in oncology, published by the American Medical Association journal JAMA Oncology, notes, “Marijuana in oncology may have potential for use as an antiemetic [relieving nausea and vomiting], for refractory cancer pain, and as an antitumor agent. However, much of the data are based on animal data, small trials, or are outdated.” The authors concluded that more research is needed into medical marijuana’s therapeutic use for cancer patients.  

There is even less research into CBD’s potential benefits for cancer patients. But still, some studies have been conducted. According to the National Cancer Institute, research indicates that CBD may slow the growth or reduce the risk of recurrence of certain kinds of cancers, including breast cancer; enhance the potency of certain medications; and reduce chemotherapy side effects including vomiting, nausea, and anxiety. However, all these studies are limited, and experts agree that further research is needed to understand just how CBD affects humans.  

Source: https://www.refinery29.com/en-us/cbd-oil-breast-cancer

PODCAST: Why #cannabis 3.0 is the real opportunity for Canada with Bruce Linton – SPONSOR: #NORTHBUD $NBUD.ca $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 12:55 PM on Wednesday, October 9th, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE
—————————–

PODCAST: Why ‘cannabis 3.0’ is the real opportunity for Canada with Bruce Linton

By: Emily Jackson

Welcome to Down to Business, a weekly podcast from the Financial Post.

It’s been one year since Canada legalized the recreational cannabis industry after a century of prohibition. But it’s just the beginning of the journey from the black market to “cannabis 3.0.”

In the lead-up to the election, Down to Business has focused on business issues with a political twist. This week, host Emily Jackson discusses the cannabis industry’s one-year legalization anniversary with Bruce Linton, the former chief executive of Canopy Growth, Canada’s largest cannabis company.

Linton discusses lessons from the first round of legalization for recreational use, what to expect from the impending introduction of cannabis infused beverages and edibles, and why Canada needs to focus on “cannabis 3.0” if it wants to be a global leader.

You can listen below — or on Apple PodcastsSpotifyStitcher and Google Play, where you can also subscribe to get new episodes every Wednesday morning.

Source: https://business.financialpost.com/cannabis/cannabis-business/down-to-business-podcast-why-cannabis-3-0-is-the-real-opportunity-for-canada

Another First for the #Pot Industry: A Licensed Cannabis Restaurant SPONSOR: NORTHBUD $NBUD.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 10:01 AM on Monday, October 7th, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE
—————————–

Another First for the Pot Industry: A Licensed Cannabis Restaurant

  • Cannabis edibles are a growing segment of the market and are expected to reach $4.1 billion in 2022, combining Canadian and U.S. sales.
  • In 2017, that figure was just $1 billion among the two countries. The segment is going to be key to the industry’s long-term growth.

By: David Jagielski

Cannabis edibles are a growing segment of the market and are expected to reach $4.1 billion in 2022, combining Canadian and U.S. sales. In 2017, that figure was just $1 billion among the two countries. The segment is going to be key to the industry’s long-term growth.

Restaurants haven’t been able to take advantage of that growth since the U.S. Food and Drug Administration has still not permitted cannabidiol (CBD) to be infused into food. While the FDA has held hearings on CBD, there’s no indication that changes are coming anytime soon.

One restaurant, however, has been able to get around that problem. Lowell Farms opened its doors earlier this month in West Hollywood, Calf., and it’s the first restaurant with a lounge licensed for cannabis use. Customers will be able to eat food and consume pot at the same establishment. That doesn’t mean the restaurant will be able to make and serve cannabis food. Instead, cannabis edibles will be permitted only if they are “produced by an outside source.” 

One of the other restrictions the restaurant will face is not being able to sell alcohol to diners. It’s a small price to pay to let them consume cannabis, since pot lounges remain a rarity in the industry. Las Vegas is among the cities looking at permitting such lounges, but that could be years away because there’s still a lot of opposition to it. 

Will a bar someday be a place to enjoy pot with friends? Image source: Getty Images.

Why lounges could be big for the industry

While marijuana has been legalized in many parts of the U.S., that doesn’t mean it’s possible to consume it at bars or sporting events, unlike alcohol where there are many places that users can drink in a social setting. Allowing that could unlock another avenue of growth for the industry.

Cannabis beverages are on the rise and expected to grow globally at a rate of more than 15% per year from now until 2025, reaching $4.5 billion in market size by then. So there’s going to be a growing need for places to enjoy such drinks with friends without always having to do so at home. And that doesn’t even factor in the growth of edibles that could be consumed at lounges, such as candy, cookies, and chocolate.

In Canada, there’s potential for Canopy Growth to test its products in one lounge that was made legal earlier this year. In many ways, the emerging Canadian cannabis edibles market, which is going to be legalized later this month and where the first products will be available in December , could prove to be a good indicator of how successful some of these concepts will be in the U.S. And for Canopy Growth, it could be an important way to get closer to breakeven.

For now, Canopy Growth can be a good opportunity for investors to take advantage of the new edibles market in Canada. Not only is the company well-positioned for success in the beverages segment, but in a recent interview with BNN Bloomberg, CEO Mark Zekulin said the company was working on more than 50 different products for the edibles market. That could lead to significant growth for Canopy Growth and get investors excited about the stock once again.

Here’s The Marijuana Stock You’ve Been Waiting For

A little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming.

Cannabis legalization is sweeping over North America – 10 states plus Washington, D.C., have all legalized recreational marijuana over the last few years, and full legalization came to Canada in October 2018.

And one under-the-radar Canadian company is poised to explode from this coming marijuana revolution.

Because a game-changing deal just went down between the Ontario government and this powerhouse company…and you need to hear this story today if you have even considered investing in pot stocks.

Source: https://www.fool.com/investing/2019/10/06/another-first-for-the-cannabis-industry-a-licensed.aspx

Vertical Exploration $VERT.ca Enters into an LOI with Venturevest Realty Partners for Note Facility to Support Significant St-Onge Wollastonite Development $TORR.ca $FA.ca $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM at 12:36 PM on Thursday, October 3rd, 2019
http://www.smallcapepicenter.com/Vert%20Square.png

VANCOUVER, BC / ACCESSWIRE / October 3, 2019 /VERTICAL EXPLORATION INC. (TSXV:VERT) (“Vertical” or “the Company”) and Venturevest Realty Partners LLC (“Venturevest”) are pleased to announce that the two companies have signed a non- binding Letter of Intent (LOI) to enter into discussions regarding the provision by Venturevest of a secured Note Facility up to a maximum amount of $20 million CAD to support the multi-phased development of the St-Onge Wollastonite Deposit.

The Note Facility would be a staged credit facility that would provide the required financing to allow Vertical to move forward with four distinct phases of St-Onge development, from the initial quarry style permitting and production phase through to the mining and final processing plant stage. Vertical views this potential Note Facility financing as a significant development that would enable the Company to rapidly develop and expand its St-Onge Wollastonite Deposit.

Further details regarding the Note Facility Agreement will be provided as soon as all terms have been negotiated between Vertical and Venturevest. The Agreement is subject to a due diligence period that is anticipated to be completed within the next 60 days. This transaction is subject to the approval of the TSX Venture Exchange.

ABOUT VENTUREVEST REALTY PARTNERS LLC.

Venturevest Realty Partners LLC (“Venturevest”) is a New York corporation.

ABOUT VERTICAL EXPLORATION

Vertical Exploration’s mission is to identify, acquire, and advance high potential mining prospects located in North America for the benefit of its stakeholders. The Company’s flagship St-Onge Wollastonite property is located in the Lac-Saint-Jean area in the Province of Quebec.

ON BEHALF OF THE BOARD

Peter P. Swistak, President/CEO

FOR FURTHER INFORMATION PLEASE CONTACT:

Telephone: 1-604-683-3995
Toll Free: 1-888-945-4770
https://vertxinc.com/